Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cue Biopharma, Inc.CUE · Entity 6301 | Director | July 09, 2026 | August 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cue Biopharma, Inc.
Report date July 09, 2026 · Filed August 28, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,900 |
Reported balance
After 2026-07-09 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-07-09 · Grant · Acquired 18,900 · Balance 18,900 F1: This amendment is being filed solely to correct an administrative calculation error in Column 4 of Table I of the original filing relating to a grant of restricted stock units ("RSUs") to the Reporting Person, which resulted in the number of securities acquired by the Reporting Person being overstated. The original filing incorrectly reported 21,800 shares; the correct amount of shares acquired is 18,900. As a result of this correction, the total amount of securities beneficially owned following the reported transaction in Column 5 has been updated to 18,900. One-third of the shares subject to the RSU vest on each of July 9, 2027, July 9, 2028 and July 9, 2029, subject to the Reporting Person's continued service with the Issuer through each such vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: This amendment is being filed solely to correct an administrative calculation error in Column 4 of Table I of the original filing relating to a grant of restricted stock units ("RSUs") to the Reporting Person, which resulted in the number of securities acquired by the Reporting Person being overstated. The original filing incorrectly reported 21,800 shares; the correct amount of shares acquired is 18,900. As a result of this correction, the total amount of securities beneficially owned following the reported transaction in Column 5 has been updated to 18,900. One-third of the shares subject to the RSU vest on each of July 9, 2027, July 9, 2028 and July 9, 2029, subject to the Reporting Person's continued service with the Issuer through each such vest date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2026 Filed Jul 10, 2026 23:37 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantCommon Stock | 21,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001974756-26-000004 · form4-07102026_110755.xml · nonDerivative · entry 1 Garzone Pamela · CIK 0001974756 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,800 F1 · shares: Represents the grant of restricted stock units ("RSUs"). One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to the reporting person's continued service with the issuer through each such vest date. Read SEC document |
| July 09, 2026 Filed Aug 28, 2026 17:04 UTC Amendment | Cue Biopharma, Inc. CUE · Entity 6301 | GrantCommon Stock | 18,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001974756-26-000006 · form4a-08282026_090821.xml · nonDerivative · entry 1 Garzone Pamela · CIK 0001974756 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,900 F1 · shares: This amendment is being filed solely to correct an administrative calculation error in Column 4 of Table I of the original filing relating to a grant of restricted stock units ("RSUs") to the Reporting Person, which resulted in the number of securities acquired by the Reporting Person being overstated. The original filing incorrectly reported 21,800 shares; the correct amount of shares acquired is 18,900. As a result of this correction, the total amount of securities beneficially owned following the reported transaction in Column 5 has been updated to 18,900. One-third of the shares subject to the RSU vest on each of July 9, 2027, July 9, 2028 and July 9, 2029, subject to the Reporting Person's continued service with the Issuer through each such vest date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 24,400 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001193125-26-004356 · ownership.xml · derivative · entry 1 Garzone Pamela · CIK 0001974756 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,400 Underlying: Common Stock · 24,400 shares Expires 2036-01-01 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This stock option becomes fully exercisable on the first anniversary of the grant date. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 24,400 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0000950170-25-001101 · ownership.xml · derivative · entry 1 Garzone Pamela · CIK 0001974756 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,400 Underlying: Common Stock · 24,400 shares Expires 2035-01-01 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 2, 2025. The option is scheduled to vest as to 50% of the underlying shares on the six-month anniversary of the grant date and as to the remaining 50% on the first anniversary of the grant date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:02 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 24,400 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0000950170-24-001833 · ownership.xml · derivative · entry 1 Garzone Pamela · CIK 0001974756 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,400 Underlying: Common Stock · 24,400 shares Expires 2034-01-01 F1 · shares: Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy. F2 · derivative.exercise_date: This option was granted on January 2, 2024. The shares underlying the option are scheduled to vest in full on the anniversary date of the grant date. Read SEC document |
| April 19, 2023 Filed Apr 21, 2023 20:15 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001209191-23-025142 · doc4.xml · derivative · entry 1 Garzone Pamela · CIK 0001974756 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-04-18 F1 · derivative.exercise_date: This stock option grant becomes exercisable over three years with one-third vesting on the one-year anniversary of the grant date and the balance vesting in eight equal quarterly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.